Bloomberg Intelligence: S&P 500 Slides as Trump's Tariff Reprieve Proves Fleeting
Watch Alix and Paul LIVE every day on YouTube: http://bit.ly/3vTiACF. Bloomberg Intelligence hosted by Paul Sweeney and Alix Steel Today's Podcast Features are: Dana D'Auria, Co-Chief Investment Officer, at Envestnet, discusses her outlook for the markets. Fear engulfed Wall Street again as US-China trade tensions escalate, sparking a plunge in stocks, the dollar and oil while bond Michael McKee, Bloomberg International Economics and Policy Correspondent,discusses today's U.S CPI data. U.S inflation cooled broadly in March, indicating some relief for consumers prior to widespread tariffs that risk contributing to price pressures. Deborah Aitken, Bloomberg Intelligence Luxury Goods Analyst, discusses Prada agreeing to buy Verace for $1.3 billlion. The Milan-based company, controlled by billionaire designer Miuccia Prada and her husband Patrizio Bertelli, is buying Versace from Capri Holdings Ltd., which paid €1.8 billion ($2 billion) for the brand in 2018. Lara Castleton, US Head of Portfolio Construction and Strategy at Janus Henderson Investors, discusses tariffs and her market outlook. A day after the biggest stock-buying wave in five years, assets tied to the economic cycle are sinking again. Traders are rushing to game out how the effective freezing of Chinese trade will impact corporate earnings, economic growth and new hiring.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
29 minutes ago
- Business Upturn
HistoSonics and Cambridge University Unveil Europe's First Edison™ Histotripsy System Powered by Li Ka Shing Foundation Gift
MINNEAPOLIS, United States: HistoSonics, the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, announced today that Addenbrookes Hospital of Cambridge University Hospital Foundation and Trust will be the first site in the United Kingdom and European continent to offer histotripsy to both NHS and private patients. This was made possible through a generous donation by the Li Ka Shing Foundation (LKSF) as well as the expedited limited market access granted by the MHRA in April 2025. This press release features multimedia. View the full release here: The milestone marks HistoSonics' official entry into the UK and European market. HistoSonics won a coveted place in the Innovative Device Access Pathway pilot in 2024 and through this program, in partnership with the DHSC, MHRA, NIHR, NHSE, and NICE expedited access to patients. HistoSonics will continue to work with UK healthcare stakeholders on our aligned goal of urgently expanding access for all NHS patients. The Li Ka Shing Foundation, established in 1980 by Hong Kong philanthropist Sir Ka-shing Li, has contributed nearly US$4 billion to advancing education, medical research and services, and poverty alleviation across the USA, UK, Canada, and Asia. Recognizing the transformative potential of technological innovation in healthcare, the Foundation's latest gift to the University of Cambridge will build upon its previous donations of five Edison systems with three to Hong Kong, one to Singapore, and one recently to Stanford University. This new gift not only heralds the introduction of the first Edison system in the UK and Europe but also celebrates the enduring partnership between the Li Ka Shing Foundation and Cambridge in their collaborative efforts to fight cancer. By supporting cutting-edge medical technologies that can deliver low cost and highly efficient solutions, the Foundation hopes to enhance patient access with improved healthcare around the world. 'This donation is an historic milestone that brings non-invasive treatment of liver tumors using histotripsy to the UK,' said Mike Blue, President and CEO, HistoSonics. 'We are grateful to the Li Ka Shing Foundation for their visionary support. With Addenbrookes as our first NHS hospital site under UCNA, we are laying the foundation for future expansion into innovation driven hospitals across the UK.' The Edison System, which received FDA De Novo clearance in October 2023, uses non-invasive therapeutic focused ultrasound energy to mechanically destroy and liquefy targeted tissue and tumors without the invasiveness or toxicity of traditional procedures, reducing the risks of bleeding, infection, and damage to surrounding non-targeted tissue. HistoSonics' initial FDA clearance is for the destruction of liver tumors, with ongoing studies focusing on kidney tumors (HOPE4KIDNEY Trial NCT05820087) and pancreas tumors (GANNON Trial NCT06282809). Professor Deborah Prentice, Vice-Chancellor of the University of Cambridge, said: 'We are very fortunate that through the generosity of Sir Ka-shing Li, Addenbrooke's Hospital in Cambridge will be able to use cutting-edge histotripsy technology to improve outcomes for NHS patients. It is technology such as this that allows Cambridge to remain at the forefront of understanding and treating tumors, a position we aim to strengthen further with Cambridge Cancer Research Hospital.' With installations soon to be in five countries including the US, UK, Hong Kong, Singapore and the United Arab Emirates, HistoSonics is actively expanding access to its histotripsy platform and is working closely with clinical leaders, national health systems, and philanthropic partners to accelerate global adoption of histotripsy as a new category of health care. HistoSonics is also pursuing broader UK and European market access via CE marking. United Kingdom Intended Use Statement: The Edison System is intended for the non-invasive mechanical destruction of liver tumours, including the partial or complete destruction of unresectable liver tumours via histotripsy. This includes malignancy linked to primary liver cancer and cases of metastatic disease in the liver. The device should only be used by people who have completed training performed by HistoSonics Inc., and its use guided by the clinical judgement of an appropriately trained physician. Users must read this user guide to understand the warnings, precautions, and clinical trial summary, including reported adverse events. The Edison System has not been evaluated for the treatment of any specific disease, including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumour progression, 5-year survival or overall survival). United States Intended Use Statement: The Edison System is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the Edison System for the treatment of any disease including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumor progression, 5-year survival or overall survival). The System should only be used by physicians who have completed training performed by HistoSonics, and its use guided by the clinical judgment of an appropriately trained physician. Refer to the device Instructions for Use for a complete list of warnings, precautions, and a summary of clinical trial results, including reported adverse events. About HistoSonics HistoSonics is a privately held medical device company developing a non-invasive platform and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquify unwanted tissue and tumors. The company is currently focused on commercializing their Edison System in the US and select global markets for liver treatment while expanding histotripsy applications into other organs like kidney, pancreas, prostate, and others. HistoSonics has offices in Ann Arbor, Michigan and Minneapolis, MN. For more information on the Edison Histotripsy System please visit: For patient-related information please visit: View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
CNBC
32 minutes ago
- CNBC
Treasury yields slip as U.S.-China trade talks enter Day 2
Treasury yields slipped Tuesday as U.S. and Chinese officials resumed trade negotiations in London for the second day. The 10-year Treasury yield was down almost 3 basis points to 4.456% at 3.30 a.m. ET. The 2-year yield slipped around one basis point to 3.993%. The 30-year yield was lower by 3 basis points to 4.921%. One basis point equals 0.01%. Yields and prices move inversely in the bond market. U.S.-China trade negotiations in London resumed on Tuesday, building on a recent call between U.S. President Donald Trump and Chinese counterpart Xi Jinping. On Monday, Treasury Secretary Scott Bessent, Commerce Secretary Howard Lutnick, and Trade Representative Jamieson Greer had talks with Chinese officials. Both sides have intensified diplomatic efforts following weeks of escalating trade tensions and uncertainty sparked by Trump's broad import tariffs on China and other key trading partners in April. "While we await any concrete news, it's worth remembering that markets have been used to a lot of back-and-forth in recent weeks," Deutsche Bank's analysts said, in reference to how U.S. tariffs slapped on China went all the way up to 145%, before being slashed to 30%, among other instances of policy reversals. "There've been several twists and turns already, and markets are getting fairly used to this uncertainty by now," wrote in a note published Tuesday. Deflation in China is also putting pressure on the Chinese government to negotiate a trade deal with Trump that benefits both countries, said Ed Yardeni, president of Yardeni Research. China's consumer prices fell for a fourth consecutive month in May, with the CPI falling 0.1% from a year earlier, data from the National Bureau of Statistics showed on Monday.
Yahoo
32 minutes ago
- Yahoo
Rolls-Royce to build Britain's first mini nuclear reactors
Rolls-Royce will build the country's first mini nuclear power plants as part of a multibillion-pound effort to make Britain a world leader in the technology. The Derby-based engineering giant was on Tuesday confirmed as the sole winner of a design competition, beating rivals GE-Hitachi and Holtec International following a two-year selection process. It will now work with the Government on a programme to initially build three the first small modular reactors (SMRs) by the 2030s, with £2.5bn of funding pledged through 2029 and billions more expected beyond that once construction begins. Ministers said the decision showed they were 'backing Britain', with the majority of the supply chain expected to be based domestically. As a 'preferred' bidder, Rolls will now hold talks to negotiate a final contract with the Government. A location has yet to be announced but sites including Wylfa, in Anglesey, and Oldbury-on-Severn, in Gloucestershire, are among those being considered. Ed Miliband, the Energy Secretary, said the scheme would boost energy security and create thousands of jobs, as part of a new 'golden age of nuclear' that has also seen the Government pledge £14bn of new funding to the construction of Sizewell C. Rachel Reeves, the Chancellor, added: 'The UK is back where it belongs, taking the lead in the technologies of tomorrow with Rolls-Royce SMR as the preferred partner for this journey. 'We're backing Britain with Great British Energy - Nuclear's ambition to ensure 70pc of supply chain products are British built, delivering our plan for change through more jobs and putting more money in people's pockets.' SMRs would in theory be faster to build than larger nuclear plants, such as Hinkley Point C and Sizewell C, and come with smaller price tags – although they remain unproven commercially. Tuesday's announcement also confirmed cutbacks to the SMR programme, which The Telegraph previously revealed were being considered. The Government had earlier suggested that two or as many as three SMR manufacturers would be chosen to take designs forward, with nuclear industry insiders saying this would boost competition and ensure a 'backup' was available should the main winner run into trouble. But with the Treasury under pressure to find billions of pounds for other priorities such as the NHS and police forces, the scale of the programme now appears to have been trimmed back. Ministers also confirmed that Great British Nuclear, the quango set up to manage the new mini-nuclear programme, would be absorbed into Mr Miliband's publicly owned Great British Energy. Tufan Erginbilgic, chief executive of Rolls-Royce, said: 'This is a very significant milestone for our business. 'It is a vote of confidence in our unique nuclear capabilities, which will be recognised by governments around the world.' Rolls has also been selected by the Czech government to build some of Europe's first SMRs in a joint venture with state energy firm CEZ. The decision brings to a close a process that was first promised by George Osborne, the former chancellor, in 2015 but did not begin until 2023 under the previous Conservative government. Rolls was widely viewed as the frontrunner in the process and had already been awarded £210m of taxpayer support in 2021 towards the development costs of its SMR technology. But in the past year, ministers have faced calls from Rolls boss Erginbilgic to push forward more quickly to ensure Britain retains 'first mover advantage'. The global SMR market is projected to be worth up to £500bn by 2050, according to the International Energy Agency. Rolls is vying against companies including Westinghouse and GE-Hitachi to secure customers and set up supply chains. The company has long supplied the pressurised water reactors that power Royal Navy submarines but has more recently sought to develop SMRs and even smaller 'micro reactors' for commercial use as well. Its SMRs would be constructed from 'modules' that are built in factories and then transported to sites for assembly. The idea is meant to ensure that the plants can be produced efficiently at scale and more quickly than larger nuclear projects. As part of the SMR competition, the Government asked companies to explain how they would bring down costs over time. In the longer run, it is also hoped that the smaller price tags of SMRs will ensure they are more attractive to private investors, which have long viewed bigger plants as too expensive and risky to back without government support. Major technology companies including Google, Amazon and Facebook owner Meta are investing in potential SMR technologies, amid suggestions they could eventually be used to supply power-hungry data centres needed to develop artificial intelligence. Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
